Nifurquinazol

Nifurquinazol
Nifurquinazol
Systematic (IUPAC) name
2,2'-{[2-(5-nitrofuran-2-yl)quinazolin-4-yl]imino}diethanol
Clinical data
Pregnancy cat.  ?
Legal status Uncontrolled
Routes  ?
Identifiers
CAS number 5055-20-9
ATC code None
PubChem CID 21139
ChemSpider 19878
UNII 44E5RRL600 YesY
KEGG D05164
Chemical data
Formula C16H16N4O5 
Mol. mass 344.32 g/mol
SMILES eMolecules & PubChem

Nifurquinazol (NF-1088) is an antibacterial agent of the nitrofuran class.[1] It was never marketed.[1]

References

  1. ^ a b Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8. http://books.google.com/?id=5S_uhYzKWisC&lpg=PA4739&dq=Nifurquinazol&pg=PA4739#v=onepage&q. 


v · d · eAntibacterials: nucleic acid inhibitors (J01E, J01M)
Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis)
2,4-Diaminopyrimidine (Trimethoprim#, Brodimoprim, Tetroxoprim, Iclaprim†)
Sulfonamides
(DHPS inhibitor)
Other/ungrouped
Combinations
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication)
1st g.
2nd g.
3rd g.
4th g.
Vet.
Related (DG)
Anaerobic DNA
inhibitors
Nitro- imidazole derivatives
Nitrofuran derivatives
RNA synthesis
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: BAC

bact (clas)

gr+f/gr+a(t)/gr-p(c)/gr-o

drug(J1p, w, n, m, vacc)
v · d · eAntiparasitics – antiprotozoal agents – Chromalveolate antiparasitics (P01)
Alveo-
late
Individual
agents
Other
DHFR inhibitors
(antifols)
2,4-Diaminopyrimidines (pyrimethamine)
biguanides (proguanil# • chlorproguanil)
Sulfadoxine • sulfamethoxypyrazine
Coformulation
Fansidar# (sulfadoxine/pyrimethamine)
Other
Atovaquone (as Malarone)
Tetracycline • Doxycycline#
Clindamycin
Combi-
nations
Fixed-dose (coformulated) ACTs
artemether-lumefantrine#
artesunate-amodiaquine (ASAQ)
artesunate-mefloquine (ASMQ)
dihydroartemisinin-piperaquine
artesunate-pyronaridine
Other combinations
(not co-formulated)
artesunate/SP • artesunate/mefloquine •
quinine/tetracycline • quinine/doxycycline • quinine/clindamycin
Hetero-
kont
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: PRO

ambz, excv, chrm (strc)

ambz, excv, chrm

ambz, excv, chrm


Stub icon This antiinfective drug article is a stub. You can help Wikipedia by expanding it.